Exogenous Testosterone (T) Alone or with Finasteride Increases Physical Performance, Grip Strength, and Lean Body Mass in Older Men with Low Serum T
The DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.
Abstract
Testosterone (T) therapy in older men with low serum T levels increases lean body mass and decreases fat mass. These changes might improve physical performance and strength; however, it has not been established whether T therapy improves functional outcome in older men. Moreover, concerns exist about the impact of T therapy on the prostate in older men. The administration of finasteride (F), which partially blocks the conversion of T to the more potent androgen, dihydrotestosterone, attenuates the impact of T replacement on prostate size and prostate-specific antigen. We hypothesized that T replacement in older, hypogonadal men would improve physical function and that the addition of F to this regimen would continue to provide the T-induced improvements in physical performance, strength, and body composition. Seventy men with low serum T (<350 ng/dl), age 65 yr and older, were randomly assigned to receive one of three regimens for 36 months: 1) T enanthate, 200 mg im every 2 wk, with placebo pills daily (T-only); 2) T enanthate, 200 mg every 2 wk, with 5 mg F daily (T + F); or 3) placebo injections and pills (placebo). We obtained serial measurements of timed physical performance, grip strength, lower extremity strength, body composition (by dual-energy x-ray absorptiometry), fasting cholesterol profiles, and hormones. Fifty men completed the 36-month protocol. After 36 months, T therapy significantly improved performance in a timed functional test when compared with baseline and placebo [4.3 +/- 1.6% (mean +/- sem, T-only) and 3.8 +/- 1.0% (T + F) vs. -5.6 +/- 1.9% for placebo (P < 0.002 for both T and T + F vs. placebo)] and increased handgrip strength compared with baseline and placebo (P < 0.05). T therapy increased lean body mass [3.77 +/- 0.55 kg (T-only) and 3.64 +/- 0.56 kg (T + F) vs. -0.21 +/- 0.55 kg for placebo (P < 0.0001)], decreased fat mass, and significantly decreased total cholesterol, low-density lipoprotein, and leptin, without affecting high-density lipoprotein, adiponectin, or fasting insulin levels. These results demonstrate that T therapy in older men with low serum T improves physical performance and strength over 36 months, when administered alone or when combined with F, and suggest that high serum levels of dihydrotestosterone are not essential for these beneficial effects of T in men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elsewhere, testosterone-associated increases in lean mass were accompanied by improvements in handgrip strength, knee extension and leg press and chest press exercises415,416.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [416]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increasing serum testosterone levels to low- to mid-normal ranges through the administration of testosterone for several months in healthy older men resulted in increased muscle strength (133–136) and improved physical performance (134, 135).”
From Health Consequences of Sarcopenic Obesity: A Narrative Review (2020) · cites this paper as [134]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Upon testosterone administration there is a decrease in fat mass and an increase in lean body mass and the net result is often, but not always, that total body weight does not show major changes.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [17]
In the citing paper
“Most randomized, placebo-controlled trials have indicated that T treatment increases lean mass and reduces fat mass in men with low serum T [2–7]”
From Causal relationship between obesity and serum testosterone status in men: A bi-directional mendelian randomization analysis (2017) · cites this paper as [4]
In the citing paper
“but the overall effect on body weight and BMI in men with different T-status is inconsistent.”
From Causal relationship between obesity and serum testosterone status in men: A bi-directional mendelian randomization analysis (2017) · cites this paper as [4]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients
Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y., Iwahashi, H., Kuriyama, H., Ouchi, N., Maeda, K., et al. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.6.1595 · Cited by 3,133 · cited 1×
“High levels of adiponectin have been suggested to be cardioprotective (44) and are associated with increased insulin sensitivity (45).”
BackgroundLongitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Feldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861
Self-citationPlasma Adiponectin Levels and Risk of Myocardial Infarction in Men
Pischon, T. (2004) · JAMA · doi:10.1001/jama.291.14.1730 · Cited by 1,773
Esposito, K., Pontillo, A., Di Palo, C., Giugliano, G., Masella, M., Marfella, R., & Giugliano, D. (2003) · JAMA · doi:10.1001/jama.289.14.1799 · Cited by 1,511
Cnop, M., Havel, P. J., Utzschneider, K. M., Carr, D. B., Sinha, M. K., Boyko, E. J., Retzlaff, B. M., Knopp, R. H., Brunzell, J. D., & Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-003-1074-z · Cited by 1,483 · cited 1×
“In cross-sectional analyses, adiponectin seems to be inversely correlated with FM (40, 41), and levels have been shown to increase with weight loss in normal subjects (42, 43).”
BackgroundYang, W.-S., Lee, W.-J., Funahashi, T., Tanaka, S., Matsuzawa, Y., Chao, C.-L., Chen, C.-L., Tai, T.-Y., & Chuang, L.-M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3815 · Cited by 1,181 · cited 1×
“In cross-sectional analyses, adiponectin seems to be inversely correlated with FM (40, 41), and levels have been shown to increase with weight loss in normal subjects (42, 43).”
BackgroundMuscle strength and speed of movement in relation to age and muscle morphology
Larsson, L., Grimby, G., & Karlsson, J. (1979) · Journal of Applied Physiology · doi:10.1152/jappl.1979.46.3.451 · Cited by 1,135
A cross-sectional study of muscle strength and mass in 45- to 78-yr-old men and women
Frontera, W. R., Hughes, V. A., Lutz, K. J., & Evans, W. J. (1991) · Journal of Applied Physiology · doi:10.1152/jappl.1991.71.2.644 · Cited by 1,011
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967 · cited 1×
“Such changes in body composition are likely due to increases in muscle mass, as has been reported in younger men receiving T (33).”
Result
Cited by
Items 401–500 of 576
Connolly, M. J., Kerse, N. M., WILKINSON, T. J., Menzies, O. H., Rolleston, A. K., Chong, Y. H., Broad, J., Moyes, S. A., Jatrana, S., & Teh, R. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016572 · Cited by 8
Yang, C., Li, C., Liu, C.-S., Lin, C., Lin, W., Li, T., & Lin, C. (2019) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.13762 · Cited by 8
Kozieł, S. M., Konarski, J. M., Konarska, A., Heuchert, J., Ignasiak, Z., & Chakraborty, R. (2024) · American Journal of Human Biology · doi:10.1002/ajhb.24078 · Cited by 9
“Males, in general, exhibit higher HGS than females of comparable age and health status (Kociuba et al., 2019), and such sexual dimorphism is often attributed to higher levels of androgenic hormones in males (Page et al., 2005).”
Butovskaya, M., Adam, Y. I., Анатольевич, Б. В., Shackelford, T. K., & Fink, B. (2024) · Early Human Development · doi:10.1016/j.earlhumdev.2024.106037 · Cited by 8
Androgen Therapy and Rehospitalization in Older Men With Testosterone Deficiency
Baillargeon, J., Deer, R., Kuo, Y., Zhang, D., Goodwin, J. S., & Volpi, E. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.03.016 · Cited by 8
Ibrahim, N. ‘., Ahmad, M. S., Zulfarina, M. S., Zaris, S. N. A. S. M., Azlin, Z. A. N., Mohamed, I. N., Mohamed, N., Mokhtar, S. A., & Shuid, A. N. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s189748 · Cited by 8
Jin, S., Hu, Y., Fu, H., Jiang, S., Xiong, Y., Qiao, H., Zhang, W., Gong, Y., & Wu, Y. (2019) · 3 Biotech · doi:10.1007/s13205-019-1857-7 · Cited by 8
Symptomatic change in Japanese hypogonadal patients several years after androgen replacement therapy
Taniguchi, H., Kawa, G., Kinoshita, H., & Matsuda, T. (2011) · The Aging Male · doi:10.3109/13685538.2011.573028 · Cited by 8
“demonstrated that administration of TE for 36 months improves physical performance and strength in older men with low serum testosterone [12].”
BackgroundTestosterone in men's health: a new role for an old hormone
Feeley, R. J., Saad, F., Guay, A. T., & Traish, A. M. (2009) · Journal of Men s Health · doi:10.1016/j.jomh.2009.06.005 · Cited by 8
Anaissie, J. E., Pastuszak, A. W., & Khera, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816665-9.00012-3 · Cited by 9
Reproductive and Nonreproductive Actions of Testosterone
Bhasin, S., & Jasuja, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65412-0 · Cited by 9
Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?
Gavrilov, Z., & Lojk, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146924 · Cited by 7
“On the other hand, the oral administration of testosterone for 3 years not only increased LBM but also significantly improved muscle performance in timed functional tests and handgrip strength [154].”
Adler, R. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-459-9_24 · Cited by 8
Handgrip and sex-specific cardiometabolic risk factors in Hispanic/Latino migrant farmworkers
Raed, A., Bilz, J., Cortez‐Cooper, M. Y., Young, L., Chen, L., Cromer, P., Zhu, H., Mazzoli, A., Parikh, S. J., Bhagatwala, J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89138-y · Cited by 7
Chen, Q., Fu, Z., Wu, X.-P., Jin, L., Li, J., Wang, Y., & Li, X. (2014) · The Aging Male · doi:10.3109/13685538.2014.896893 · Cited by 7
Vanderschueren, D., Sinnesael, M., Gielen, E., Claessens, F., & Boonen, S. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003353.009 · Cited by 9
Saad, F., Haider, A., Giltay, E. J., & Gooren, L. J. (2011) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci.2010.081 · Cited by 7
Visvanathan, R., Piantadosi, C., Lange, K. M., Naganathan, V., Hunter, P., Cameron, I. D., & Chapman, I. M. (2016) · The journal of nutrition health & aging · doi:10.1007/s12603-016-0689-y · Cited by 7
“Short-term administration of the anabolic hormone testosterone has been shown to increase muscle size and strength and, inconsistently, function and quality of life in older people (18-20), while longer-term testosterone administration to older people has produced only minor functional benefits, perhaps confined to me…”
InfluentialAssociation of visual conscious experience vividness with human cardiopulmonary function
Sun, Y., Xue, X., Li, Z., Ma, H., & Zhang, D. (2023) · Stress and Brain · doi:10.26599/sab.2022.9060033 · Cited by 6
Otzel, D. M., Nichols, L., Conover, C. F., MARANGI, S. A., Kura, J. R., Iannaccone, D. K., Clark, D. J., Gregory, C. M., Sonntag, C. F., Wokhlu, A., et al. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1479264 · Cited by 7
Sante, S. D., Conners, W. P., & Morgentaler, A. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02557.x · Cited by 6
Dhindsa, S., Irwig, M. S., & Wyne, K. L. (2018) · Endocrine Practice · doi:10.4158/ep-2017-0131 · Cited by 7
ORWOLL, E. S., Vanderschueren, D., & Boonen, S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00032-7 · Cited by 8
The relationship between testosterone deficiency and frailty in elderly men
Saad, F. (2010) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci.2010.060 · Cited by 7
Testosterone: More Is Not Always Better
Khosla, S. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2134 · Cited by 7
Treating Hypopituitarism in the Over 65s: Review of Clinical Studies
Paragliola, R. M., Locantore, P., Corsello, S. M., & Salvatori, R. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s370782 · Cited by 6
Tung, D. S., & Cunningham, G. R. (2007) · The Endocrinologist · doi:10.1097/01.ten.0000260860.68375.96 · Cited by 7
Androgen Replacement Therapy in Hypogonadal Men
Wang, C., & Swerdloff, R. S. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-727-7_18 · Cited by 7
Is Men's Health Just a Single Letter?
Anawalt, B. D. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4362 · Cited by 7
Self-citationJing, C., Deckey, D. G., Rosas, S., Stein, M. K., Bolognesi, M. P., & Ryan, S. P. (2025) · Orthopedics · doi:10.3928/01477447-20251104-01 · Cited by 5
Testosterone and male rejuvenation
Helo, S., Thomas, P., & Tadros, N. N. (2019) · Panminerva Medica · doi:10.23736/s0031-0808.18.03513-9 · Cited by 5
Haider, A., Gooren, L. J., Padungtod, P., & Saad, F. (2009) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci.2010.002 · Cited by 5
Obesity’s role in secondary male hypogonadism: a review of pathophysiology and management issues
Seyam, O., Gandhi, J., Joshi, G. S., Smith, N. L., & Khan, S. A. (2019) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-019-00056-7 · Cited by 5
Boirie, Y., & Mirand, P. P. (2007) · Springer eBooks · doi:10.1007/978-2-287-33475-7_36 · Cited by 5
Sumii, K., Miyake, H., Enatsu, N., Matsushita, K., & Fujisawa, M. (2015) · Andrologia · doi:10.1111/and.12433 · Cited by 5
“…diagnosed with LOH without considerable adverse events related to this therapy (Amory et al., 2004; Cavallini et al., 2004; Cherrier et al., 2005; Page et al., 2005); therefore, TRT is currently regarded as the standard treatment for aging men with testosterone deficiency who have clinical signs…”
BackgroundKoley, S., & Khanna, A. (2014) · Journal of Physical Therapy and Health Promotion · doi:10.18005/pthp0201002 · Cited by 5
Allan, C. A., & McLachlan, R. I. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00139-8 · Cited by 5
Testosteron und das metabolische Syndrom
Schubert, M., & Jockenhövel, F. (2010) · Der Urologe · doi:10.1007/s00120-009-2198-7 · Cited by 4
Herring, M. J. (2014) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000115 · Cited by 4
Pavey, H., Polkey, M. I., Bolton, C. E., Cheriyan, J., McEniery, C. M., Wilkinson, I. B., Mohan, D., Casaburi, R. H., Miller, B. E., Tal‐Singer, R., et al. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001601 · Cited by 4
An anthropological perspective on hand grip strength as a marker of health, disease and fitness
AYDIK, M. F., & Ertuğrul, B. (2023) · Hitit Sosyal Bilimler Dergisi · doi:10.17218/hititsbd.1240719 · Cited by 7
“( Chiu et al., 2020; Bhasin et al., 2001; Page et al., 2005) Testosterone is responsible for developing secondary sexual characteristics in human as well as increasing the muscle mass and causing the divergence in physical strength in sexes.”
Developments and challenges for new and emergent preparations for male hypogonadism treatment
Corona, G., Sparano, C., Rastrelli, G., Vignozzi, L., & Maggi, M. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2276760 · Cited by 2
“Interestingly, while T alone induced an increase in PSA and prostate volume, the addition of finasteride prevented the PSA increase and blunted the rise in prostate volume [76].”
BackgroundInfluentialGooren, L. J. (2006) · The Journal of Men s Health and Gender · doi:10.1016/j.jmhg.2006.10.002 · Cited by 4
“Another recent study confirms this result [39].”
Frailty and its relationship to late onset hypogonadism
Gooren, L. J. (2007) · The Journal of Men s Health and Gender · doi:10.1016/j.jmhg.2007.09.002 · Cited by 5
Allan, C. A., & McLachlan, R. I. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00139-6 · Cited by 7
Clinical Evaluation of Leydig Cell Function
Swerdloff, R. S., & Wang, C. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-453-7_30 · Cited by 4
“Testosterone, in physiological doses, will reverse the muscle wasting seen in hypogonadal men and pharmacological doses will enhance these parameters in normal men (45,46, 51 ).”
BackgroundEffects of Testosterone Therapy in Older Men
Page, S. T., & Matsumoto, A. M. (2008) · JAMA · doi:10.1001/jama.299.16.1900-a · Cited by 4
Self-citationHigher adiponectin and lower hemoglobin levels in older men: causal or confounded by androgens?
Schooling, C. M., & Zhao, J. V. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12362 · Cited by 4
Androgen Effects on the Skeletal Muscle
Bhasin, S., Singh, R., Jasuja, R., & Storer, T. W. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374602-3.00027-4 · Cited by 4
Androgen Deficiency in the Aging Male
Morales, Á. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00029-3 · Cited by 6
Klinaki, E., & Ogrodnik, M. B. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111929 · Cited by 3
Testosterone, the metabolic syndrome and diabetes mellitus
Heufelder, A. E. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2008.03.013 · Cited by 5
“A study of elderly hypogonadal men receiving testosterone treat-ment found no changes in plasma insulin levels [55].”
Čeponis, J., Wang, C., Swerdloff, R. S., & Liu, P. Y. (2017) · Endocrinology · doi:10.1007/978-3-319-29456-8_11-1 · Cited by 3
Park, T. Y., Choi, M., Kim, D. S., Yeo, J. K., Rajasekaran, M. R., & Park, M. G. (2023) · The World Journal of Men s Health · doi:10.5534/wjmh.220274 · Cited by 3
“Testosterone treatment (TT) increases grip strength and lean body mass and enhances physical performance in hypogo-nadal men [4,5].”
BackgroundErtuğrul, B., & AYDIK, M. F. (2023) · Current Research in Social Sciences · doi:10.30613/curesosc.1195115 · Cited by 3
Schwartz, E., Morelli, V., & Holtorf, K. (2011) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2011.07.004 · Cited by 4
Testosterone Supplementation in Hypogonadal Men on 5‐ARI Therapy
Nickel, J. C., & Carson, C. C. (2014) · Sexual Medicine Reviews · doi:10.1002/smrj.27 · Cited by 3
Nabipour, I., Ebeling, P. R., & Seibel, M. J. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.45 · Cited by 3
Single and Combined Effects of Growth Hormone and Testosterone in Healthy Older Men
WELTMAN, A. L., & Veldhuis, J. D. (2006) · Hormone Research in Paediatrics · doi:10.1159/000096623 · Cited by 3
Novel Strategies for Improving Physical Function
Bhasin, S., Jasuja, R., Tu, P., Storer, T. W., & Guo, W. (2011) · Hormone Research in Paediatrics · doi:10.1159/000329148 · Cited by 3
Mancini, A., Raimondo, S., Segni, C. D., Gadotti, G., Giacchi, E., Zollino, M., Bonomi, M., Persani, L., & Pontecorvi, A. (2014) · Cited by 3
Androgen deficiency in aging men
T'Sjoen, G. G., & Kaufman, J. (2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000224805.31695.6a · Cited by 3
Testosterone Replacement Therapy in Men and Women
El‐Maouche, D., & Dobs, A. S. (2010) · Principles of Gender-Specific Medicine · doi:10.1016/b978-0-12-374271-1.00060-5 · Cited by 5
Králik, M., Cvečka, J., Buzgó, G., Putala, M., Ukropcová, B., Ukropec, J., Killinger, Z., Payer, J., Kollárik, B., Bujdák, P., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025991 · Cited by 3
Testosterone responses to exhausting exercise in male and female students
Baydil, B. (2020) · African Educational Research Journal · doi:10.30918/aerj.82.20.054 · Cited by 3
“Physiological function of testosterone is to maintain skeletal muscle tissues and lead to an increase in muscle mass via genomic mechanisms and thus resulting in muscle mass increase, there are some studies supporting this phenomenon (Page et al., 2005).”
BackgroundČeponis, J., Wang, C., Swerdloff, R. S., & Liu, P. Y. (2017) · Endocrinology · doi:10.1007/978-3-319-44441-3_11 · Cited by 3
Overall Approach to the Evaluation and Treatment of Osteoporosis in Men
ORWOLL, E. S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374602-3.00048-1 · Cited by 2
Benefits and Risks of Testosterone Therapy in Men With Testosterone Deficiency
Traish, A. M., & Morgentaler, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813197-8.00018-x · Cited by 2
Nonhuman Primate Models of Immunosenescence
Rivera, A., Rais, M., Barr, T., Arnold, N. D., Sureshchandra, S., & Messaoudi, I. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_80 · Cited by 2
Androgen Replacement Therapy in Hypogonadal Men
Čeponis, J., Swerdloff, R. S., & Wang, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-53298-1_18 · Cited by 2
Testosterone Therapy for Dropped Head Syndrome: A Case Report
Felong, T. J., Balos, L. L., & Silvestri, N. J. (2022) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0000000000000372 · Cited by 2
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · Cited by 4
Self-citationORWOLL, E. S. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch62 · Cited by 3
Androgen deficiency in the male
Mitchell, G. C., & Hellstrom, W. J. G. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9780511997761.010 · Cited by 2
Morley, J. E., & Moon, K. J. (2012) · Wiley eBooks · doi:10.1002/9781119952930.ch95 · Cited by 2
Testosterone: clinical relevance in ageing men
Huupponen, R., Huhtaniemi, I. T., & Lehtonen, A. (2009) · Reviews in Clinical Gerontology · doi:10.1017/s0959259809990372 · Cited by 2
De, S., Sengupta, P., Maity, P., Pal, A., & Dhara, P. C. (2011) · Isokinetics and Exercise Science · doi:10.3233/ies-2011-0423 · Cited by 2
“as job demand [24].”
Sexual dimorphism in hand grip strength and hand dimensions among Hausas
Umar, K. B., Danborno, B., Olorunshola, K., & Adamu, L. H. (2016) · Annals of Bioanthropology · doi:10.4103/2315-7992.204687 · Cited by 2
Testosterone and Physical Function
Yalamanchi, S., Kalyani, R. R., Buta, B. J., & Dobs, A. S. (2017) · Current Sexual Health Reports · doi:10.1007/s11930-017-0136-z · Cited by 2
“In contrast, Page et al. (2005) demonstrated in a 36-month trial including hypogonadal men ≥ 65 years of age (n = 70; serum total testosterone < 350 ng/dl) that testosterone, with or without finasteride, improved lean body mass, decreased fat mass, increased handgrip, but no change in lower…”
Snyder, P. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4907-4.00015-2 · Cited by 2
Clinically Important Differences for Mobility Measures Derived from the Testosterone Trials
Stephens‐Shields, A. J., Farrar, J. T., Ellenberg, S. S., Storer, T. W., Gill, T. M., Basaria, S. S., Pahor, M., Cauley, J. A., Ensrud, K. E., Preston, P. E., et al. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16942 · Cited by 2
“Many pharmacologic therapies, such as testosterone, selective androgen receptor modulators, myostatin-activin antagonists, growth hormone secretagogs, and troponin activators are being developed to treat aging- or chronic diease-associated mobility limitation; efficacy trials have typically included community-dwelling…”
MethodAge-Related Testosterone Deficiency Merits Treatment
Traish, A. M. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0019 · Cited by 4
Eidelberg, A., Cho, A., & Chughtai, B. I. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819765-3.00015-7 · Cited by 2
Choong, K. L. M., Jasuja, R., Basaria, S. S., Storer, T. W., & Bhasin, S. (2010) · Endocrine updates · doi:10.1007/978-1-4419-7014-5_9 · Cited by 3
ORWOLL, E. S., & Adler, R. A. (2018) · Wiley eBooks · doi:10.1002/9781119266594.ch56 · Cited by 2
Impact of Testosterone Deficiency and Testosterone Therapy on Men’s Health
Traish, A. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_13 · Cited by 1
Zhao, Y., & Zhang, P. (2025) · PubMed Central · doi:10.11817/j.issn.1672-7347.2025.240509 · Cited by 4
“2 握力下降对慢性病共病风险的影响 慢性病共病数量与握力呈负相关,而握力下降 同样可导致慢性病共病患病风险与患病率增加。韩 国国民健康和营养调查相关研究 [38] 显示男性和女性握 Balogun 等 [39] 研究发现相对握力 ( 握力 / 体重 ) 较高者慢 性病共病发生风险较低,并且较低的相对握力与较 高的慢性病共病发生风险呈线性相关,但绝对握力 与慢性病共病发生风险无显著相关性。刘佳佳等 [40] 的 性单独使用睾酮或与非那雄胺联合治疗能够显著提 升其肌肉力量水平 [46-47] 。 1 .”
Recent advances in the research of sarcopenia in colorectal cancer
Wang, Y., Wang, Y., & Liu, M. R. (2025) · Holistic Integrative Oncology · doi:10.1007/s44178-025-00210-3 · Cited by 1
Androgens, visceral obesity and the risks for cardiovascular disease and diabetes mellitus
Gooren, L. J. (2007) · The Journal of Men s Health and Gender · doi:10.1016/j.jmhg.2007.02.001 · Cited by 1
Can the administration of testosterone to men with late-onset hypogonadism be discontinued?
Gooren, L. J. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2008.09.005 · Cited by 1
“In fact, testosterone treatment of the metabolic syndrome is not always associated with a reduction in weight [38,43].”
Santos, L. A., Vale, R. G. D. S., de Mello, D. B., Giani, T. S., & Dantas, E. H. M. (2011) · journal of physical education · doi:10.4025/reveducfis.v22i1.9071 · Cited by 1
Testosterone therapy and sexual health in hypogonadal men
Dupree, J. M. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.66 · Cited by 1
Jackson, T., Wilson, D. V., & Greig, C. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-43365-3_9 · Cited by 1
Endocrinology of male sexual dysfunction
Janmohamed, S. G., & Bouloux, P.-M. G. (2016) · Wiley eBooks · doi:10.1002/9781118746509.ch5 · Cited by 2
Profil biologique des patients âgés fragiles
Célarier, T., Chol, C., & Gonthier, R. (2009) · Springer eBooks · doi:10.1007/978-2-287-93911-2_3 · Cited by 1
Nucci, R. A. B., Tanasov, V. S., Neto, W. K., de Souza, R., & Gama, E. F. (2018) · Journal of Morphological Sciences · doi:10.1055/s-0038-1669470 · Cited by 1
Snyder, P. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2758-2.00016-0 · Cited by 2
Therapeutic Strategies to Spinal Cord Injury
Jendelová, P. (2018) · MDPI eBooks · doi:10.3390/books978-3-03897-407-9 · Cited by 2
Safety of androgen therapy in men with prostate cancer
Rajan, P., Tharakan, T., & Chen, R. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101628 · Cited by 2
Thomas, D. R. (2012) · Wiley eBooks · doi:10.1002/9781119952930.ch17 · Cited by 1
Metadata
- Authors
- Page, S. T., Amory, J. K., Bowman, F. D., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L.
- Affiliations
- Emory University (US)
- VA Puget Sound Health Care System (US)
- University of Washington (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-03
- Volume
- 90
- Issue
- 3
- Pages
- 1502-1510
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2116827517
- Cited by
- 566
- References
- 49
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 10 · 2023: 14 · 2022: 20 · 2021: 12 · 2020: 16 · 2019: 26 · 2018: 30 · 2017: 31 · 2016: 29 · 2015: 22 · 2014: 34 · 2013: 24 · 2012: 34
- FWCI
- 25.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- ResearchWorks at the University of Washington (University of Washington) (submittedVersion)
- Funders
- National Institutes of Health (5r01ag010975-04, HL007028)
- National Institute on Aging (K23AG027238, AG10975)
- National Heart, Lung, and Blood Institute (HL-007028, T32HL007028)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, finasteride, hypogonadism, older men, physical performance, grip strength, lean body mass, body composition, testosterone enanthate, prostate-specific antigen, cholesterol, leptin, functional performance, lower limb strength
- MeSH terms
- Aged, Aged, 80 and over, Aging, Androgens, Body Composition, Double-Blind Method, Drug Therapy, Combination, Enzyme Inhibitors, Humans, Hypogonadism, Insulin, Lipids, Male, Motor Activity, Testosterone, Body Mass Index, Finasteride, Hand Strength, Leptin, Intercellular Signaling Peptides and Proteins, Adiponectin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.